In silico cancer modeling: is it ready for prime time?
At the dawn of the era of personalized, systems-driven medicine, computational or in silico modeling and the simulation of disease processes is becoming increasingly important for hypothesis generation and data integration in both experiments and clinics alike. Arguably, the use of these techniques is nowhere more visible than in oncology. To illustrate the field's vast potential, as well as its current limitations, we briefly review selected studies on modeling malignant brain tumors. Implications for clinical practice, and for clinical trial design and outcome prediction, are also discussed.
Deisboeck
Thomas S
TS
Complex Biosystems Modeling Laboratory, Harvard-MIT Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital-East, 13th Street, Charlestown, MA 02129, USA. deisboec@helix.mgh.harvard.edu
Zhang
Le
L
Yoon
Jeongah
J
Costa
Jose
J
D001932:Brain Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000379:methods*; D003198:Computer Simulation; D017076:Computer-Aided Design; D006801:Humans; D010597:Pharmacogenetics; D012107:Research Design / Q000592:standards*; D049490:Systems Biology